Endoscopic therapy or surveillance for Barrett’s esophagus with low-grade dysplasia: time to involve patients in shared decision making

Degree of dysplasia remains the best predictor of malignant progression in Barrett’s esophagus (BE). Although the management approaches to nondysplastic BE and BE with high-grade dysplasia (HGD) have been clearly established as surveillance and endotherapy, respectively, the management of BE with low-grade dysplasia (LGD) remains controversial. Professional society guidelines have changed over time with the evolution of literature on BE-LGD.